Cellectis Presents Preclinical Data on TALEN®-Edited MUC1-CAR T Cells…
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) – Cellectis (the “Company”) CLLSa clinical-stage biotechnology company using its breakthrough gene-editing platform to develop life-saving cell and